David Epstein - Evelo Biosciences Director
| EVLODelisted Stock | USD 0.09 0.17 66.00% |
Director
Mr. David R Epstein is the Director of the Company. He has served as a member of our board of directors since March 2017. David is executive partner at Flagship Pioneering and executive chairman of Flagshipfounded Rubius Therapeutics. Most recently, he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG, from 2010 to mid2016. Previously, David started up and led Novartis Oncology and Molecular Diagnostic units. Under his leadership, the companys oncology business grew to the second largest in the world. David has more than 25 years of extensive globalscale drug development, deal making, commercialization and leadership experience. since 2017.
| Tenure | 7 years |
| Phone | 617 577 0300 |
| Web | https://www.evelobio.com |
Evelo Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.8325) % which means that it has lost $0.8325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (62.3276) %, meaning that it created substantial loss on money invested by shareholders. Evelo Biosciences' management efficiency ratios could be used to measure how well Evelo Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 51.14 M in liabilities with Debt to Equity (D/E) ratio of 1.55, which is about average as compared to similar companies. Evelo Biosciences has a current ratio of 4.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Evelo Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evelo Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evelo Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evelo to invest in growth at high rates of return. When we think about Evelo Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jorgen Nordlund | Windtree Therapeutics | 51 | |
| Mark Auerbach | Assembly Biosciences | 78 | |
| Anne Urlwin | Instil Bio | N/A | |
| Michael Maslowski | Instil Bio | N/A | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Geoffrey Swier | Instil Bio | N/A | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Gaurav Swarup | Instil Bio | 60 | |
| Marvin Rosenthale | Windtree Therapeutics | 80 | |
| Wayne Kauth | Instil Bio | 79 | |
| Bruce Peacock | Windtree Therapeutics | 66 | |
| Alan Lewis | Assembly Biosciences | 71 | |
| Seth Harrison | Aileron Therapeutics | 56 | |
| Virgil Thompson | Processa Pharmaceuticals | 77 | |
| Patrick Lin | Processa Pharmaceuticals | 59 | |
| Mahady Joseph | Windtree Therapeutics | 62 | |
| Tridibesh Mukherjee | Instil Bio | 74 | |
| Veena Hingarh | Instil Bio | N/A | |
| TsungShann EMBA | ABVC Biopharma | 70 | |
| Fiona Oliver | Instil Bio | N/A | |
Management Performance
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 |
Evelo Biosciences Leadership Team
Elected by the shareholders, the Evelo Biosciences' board of directors comprises two types of representatives: Evelo Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evelo. The board's role is to monitor Evelo Biosciences' management team and ensure that shareholders' interests are well served. Evelo Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evelo Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zung, Chief Officer | ||
| Simba Gill, CEO, Director | ||
| David Perry, Director | ||
| Leslie WardwellScott, VP Integration | ||
| Jessica Cotrone, VP Communications | ||
| Lord Darzi, Director | ||
| Nancy Simonian, Director | ||
| Balkrishan Gill, CEO Pres | ||
| David Epstein, Director | ||
| Noubar Afeyan, Chairman of the Board | ||
| Duncan McHale, Chief Medical Officer | ||
| Kendra Sweeney, Head Markets | ||
| Stephen Carriere, VP Officer | ||
| Mark Bodmer, Chief Scientific Officer and Presidentident of Research and Development | ||
| Jonathan Poole, CFO | ||
| JoseCarlos GutierrezRamos, Director | ||
| Chun Zhang, Chief Officer | ||
| Julie Carretero, Chief Officer | ||
| Humphrey Gardner, Chief of Medical Oncology | ||
| Theodose MelasKyriazi, Director | ||
| Marella Thorell, CFO Treasurer |
Evelo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evelo Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 83.13 % | ||||
| Number Of Shares Shorted | 430.1 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) |
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evelo Pink Sheet
| 0.9 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
Moving against Evelo Pink Sheet
| 0.82 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
| 0.74 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.71 | VANI | Vivani Medical | PairCorr |
| 0.7 | VERA | Vera Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.68 | YS | YS Biopharma | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |